LAUSR

ABSTRACT The effect of topical co‐administration of promoter drugs with paclitaxel to increase anti‐tumor effects of paclitaxel was investigated. Mice with orthotopic 4T1‐Luc breast cancer received single intra‐tumoral injection of a polymeric formulation with paclitaxel and a specific promoter drug. Several promoter drugs were evaluated, including: dexamethasone, losartan, nicotinamide, Azone, and oleic acid. Dexamethasone exhibited the highest effect on paclitaxel anti‐tumor activity, in a dose‐dependent fashion. However, this effect was accompanied by systemic effects of dexamethasone, and inability to prevent tumor metastasis to the lungs. Topical co‐administration of promoter drugs with anti‐cancer agents can enhance their anti‐tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti‐cancer drugs, and their suitability for the clinical management of the breast cancer disease.